In recent past respiratory seasons, the world witnessed a “tripledemic” of Influenza (flu), SARS-CoV-2 (COVID-19), and Respiratory Syncytial Virus (RSV). In this presentation, I will discuss the primary microbiology, epidemiology, control, prevention, vulnerable populations, the importance of laboratory validation, and the benefits of molecular-based testing of these three primary respiratory season pathogens. The 2024-25 landscape will likely be different, with new virus variants, new vaccines and treatments, like the game-changing antibody that protects children from RSV. The healthcare and public health community have also learned some valuable lessons going forward with the ever-evolving respiratory agents. How can we all best prepare for the upcoming season?